Stemline Therapeutics Inc (STML) Sees Significant Growth in Short Interest

Stemline Therapeutics Inc (NASDAQ:STML) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 1,593,549 shares, a growth of 16.2% from the March 15th total of 1,371,249 shares. Based on an average daily volume of 280,426 shares, the days-to-cover ratio is currently 5.7 days.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 4,000 shares of the company’s stock in a transaction on Monday, February 27th. The shares were sold at an average price of $6.97, for a total value of $27,880.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Ivan Bergstein sold 17,980 shares of the company’s stock in a transaction on Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $125,680.20. The disclosure for this sale can be found here. Insiders sold a total of 52,653 shares of company stock valued at $364,803 over the last 90 days. Company insiders own 16.70% of the company’s stock.

Large investors have recently modified their holdings of the stock. Nationwide Fund Advisors raised its stake in shares of Stemline Therapeutics by 7.8% in the first quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 858 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Stemline Therapeutics by 7.9% in the fourth quarter. Renaissance Technologies LLC now owns 65,500 shares of the biopharmaceutical company’s stock worth $701,000 after buying an additional 4,800 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Stemline Therapeutics by 30.8% in the fourth quarter. Teachers Advisors LLC now owns 35,195 shares of the biopharmaceutical company’s stock worth $377,000 after buying an additional 8,282 shares in the last quarter. Perceptive Advisors LLC purchased a new stake in shares of Stemline Therapeutics during the fourth quarter worth approximately $115,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its stake in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares in the last quarter. Hedge funds and other institutional investors own 37.76% of the company’s stock.

Several research analysts recently issued reports on the stock. HC Wainwright set a $34.00 price target on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research note on Sunday, January 8th. Wedbush decreased their price target on shares of Stemline Therapeutics from $19.00 to $11.00 and set an “outperform” rating for the company in a research note on Monday, February 6th. Ladenburg Thalmann Financial Services set a $41.00 price target on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 20th. Cowen and Company reiterated a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, March 23rd. Finally, Jefferies Group LLC set a $16.00 price target on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research note on Friday, February 3rd. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $24.33.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 2.81% during mid-day trading on Friday, reaching $8.65. 96,674 shares of the company traded hands. The firm has a 50 day moving average of $8.70 and a 200-day moving average of $10.40. The stock’s market capitalization is $155.28 million. Stemline Therapeutics has a 52 week low of $4.79 and a 52 week high of $14.60.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/04/21/stemline-therapeutics-inc-stml-sees-significant-growth-in-short-interest.html.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply